Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Model-informed Drug Development
Model-informed Drug Development
Type here to filter the list
044: Effect of Food on the Pharmacokinetics & Safety Profile of p53 Reactivator Rezatapopt in Healthy Subjects & Patients With Solid Tumors Harboring a
TP53
Y220C Mutation
Favorite
045: Population Pharmacokinetics of GB-5001, a Long-acting Intramuscular Injection of Donepezil, in Healthy Participants
Favorite
046: Exposure-Response Analysis to Inform QT Prolongation Potential for Cedirogant
Favorite
047: How Much PK Data Do We Really Need in Phase 3? A Milvexian Case Study
Favorite
048: Population Pharmacokinetic and Exposure-response Analyses of anti-BDCA2 Antibody Litifilimab Support Its Clinical Benefit for Cutaneous Lupus Erythematosus
Favorite
049: Assessment of the Effect of HBV Viral Genotype on Bepirovirsen Efficacy Using a Population Pharmacokinetic/Pharmacodynamic Modeling Approach
Favorite
050: Modeling Effects of Lymphodepletion Therapy on CAR T-cell & Cytokine Dynamics
Favorite
051: Pharmacokinetically-Guided Dosing of Fludarabine for Lymphodepletion in CAR T-cell Therapy: A Clinical Trial Simulation Study
Favorite
